<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04640246</url>
  </required_header>
  <id_info>
    <org_study_id>TBX-3400-003</org_study_id>
    <nct_id>NCT04640246</nct_id>
  </id_info>
  <brief_title>Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies</brief_title>
  <official_title>A Phase 1 Single-Center Dose-Escalation Study of the Safety, Tolerability and Early Efficacy of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiga Biotechnologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiga Biotechnologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of treatment with TBX-3400 in subjects with solid malignant tumors that are&#xD;
      resistant or refractory to standard therapies.&#xD;
&#xD;
      The subject's own blood cells are exposed to a protein that has been shown in the laboratory&#xD;
      to result in anti-tumor activity.&#xD;
&#xD;
      The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the&#xD;
      body's immune response to the tumor.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the incidence and severity of treatment-emergent adverse events (TEAEs), including the incidence of dose-limiting toxicities (DLTs), graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</measure>
    <time_frame>8 months</time_frame>
    <description>Adverse events from subject reporting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Responses as defined by RECIST</measure>
    <time_frame>8 months</time_frame>
    <description>Tumor measurements to assess disease state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of concentrations of certain proteins such as cluster of differentiation 69 (CD69), as biomarkers of activity of TBX-3400</measure>
    <time_frame>8 months</time_frame>
    <description>Preliminary efficacy assessment to measure activity of TBX-3400</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and/or concentration of anti TBX-3400 antibodies</measure>
    <time_frame>8 months</time_frame>
    <description>Measure of immunogenicity of TBX-3400</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quantification of the concentration of interleukin-1 (IL-1) in plasma</measure>
    <time_frame>8 months</time_frame>
    <description>Preliminary efficacy assessment to measure activity of TBX-3400</description>
  </other_outcome>
  <other_outcome>
    <measure>Quantification of the concentration of interleukin-6 (IL-6) in plasma</measure>
    <time_frame>8 months</time_frame>
    <description>Preliminary efficacy assessment to measure activity of TBX-3400</description>
  </other_outcome>
  <other_outcome>
    <measure>Quantification of the concentration of interferon-alpha (IFN-α) in plasma</measure>
    <time_frame>8 months</time_frame>
    <description>Preliminary efficacy assessment to measure activity of TBX-3400</description>
  </other_outcome>
  <other_outcome>
    <measure>Quantification of the concentration of interferon-gamma inducible protein 10kD (IP-10) in plasma</measure>
    <time_frame>8 months</time_frame>
    <description>Preliminary efficacy assessment to measure activity of TBX-3400</description>
  </other_outcome>
  <other_outcome>
    <measure>Quantification of the concentration of interferon-gamma (IFN-γ) in plasma</measure>
    <time_frame>8 months</time_frame>
    <description>Preliminary efficacy assessment to measure activity of TBX-3400</description>
  </other_outcome>
  <other_outcome>
    <measure>Quantification of the concentration of transforming growth factor-beta (TGF-ß) in plasma</measure>
    <time_frame>8 months</time_frame>
    <description>Preliminary efficacy assessment to measure activity of TBX-3400</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cancer</condition>
  <condition>Tumor, Solid</condition>
  <condition>Refractory Cancer</condition>
  <arm_group>
    <arm_group_label>TBX-3400</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBX-3400 by intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TBX-3400</intervention_name>
    <description>Autologous transfusion</description>
    <arm_group_label>TBX-3400</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following inclusion criteria to be eligible for participation&#xD;
        in the study:&#xD;
&#xD;
          1. Histologically or cytologically confirmed diagnosis of malignant solid tumor/s&#xD;
&#xD;
          2. Male or female subjects age 18 or older&#xD;
&#xD;
          3. Metastatic tumor that has failed at least one line of therapy with further options&#xD;
             being non-curative; or with metastatic tumor and patient refuses conventional&#xD;
             treatment, at the discretion of the investigator&#xD;
&#xD;
          4. At least 30 days since the last dose of medication to treat their malignancy, or, at&#xD;
             investigator discretion, at least 7 days since last dose of treatment with medication&#xD;
             with a short half-life.&#xD;
&#xD;
          5. Measurable or evaluable disease by RECIST version 1.1&#xD;
&#xD;
          6. Capable of understanding and complying with protocol requirements&#xD;
&#xD;
          7. A life expectancy of greater than 12 weeks at Screening&#xD;
&#xD;
          8. ECOG Performance Status of 0 to 2&#xD;
&#xD;
          9. Written informed consent from the patient or the patient's legally acceptable&#xD;
             representative prior to the initiation of any study procedures&#xD;
&#xD;
         10. Adequate bone marrow, liver, and renal function at screening as defined below:&#xD;
&#xD;
               -  hemoglobin ≥8.0 g/dL (transfusions allowed)&#xD;
&#xD;
               -  total lymphocyte count ≥500/µL&#xD;
&#xD;
               -  absolute neutrophil count ≥1500/µL&#xD;
&#xD;
               -  platelet count ≥100,000/µL (transfusions allowed)&#xD;
&#xD;
               -  alanine transaminase and aspartate transaminase ≤3.0 times the upper limit of&#xD;
                  normal (ULN), or ≤5 times ULN for subjects with known hepatic metastases&#xD;
&#xD;
               -  total serum bilirubin ≤1.5 x the ULN; ≤2.0 x the ULN if liver metastases are&#xD;
                  present; subjects with a known history of Gilbert's syndrome (≤3.0 x the ULN)&#xD;
                  and/or isolated elevations of indirect bilirubin are eligible for study&#xD;
                  participation&#xD;
&#xD;
               -  estimated glomerular filtration rate ≥50 mL/min/1.73 m2 (using Cockcroft Gault&#xD;
                  formula)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following criteria will not be eligible for participation in&#xD;
        the study:&#xD;
&#xD;
          1. Pregnant or breast feeding&#xD;
&#xD;
          2. Require systemic pharmacologic doses of corticosteroids at or above the equivalent of&#xD;
             10 mg/day of prednisone; replacement doses, topical, ophthalmologic and inhalational&#xD;
             steroids are permitted&#xD;
&#xD;
          3. Active, symptomatic central nervous system (CNS) metastases. Subjects with CNS&#xD;
             metastases are eligible for the trial if the metastases have been treated by surgery&#xD;
             and/or radiotherapy and the patient is off corticosteroids and is neurologically&#xD;
             stable for at least 7 days prior to screening&#xD;
&#xD;
          4. Any concurrent uncontrolled illness, including mental illness or substance abuse,&#xD;
             which in the opinion of the investigator would make the patient unable to cooperate or&#xD;
             participate in the trial&#xD;
&#xD;
          5. Severe uncontrolled cardiac disease within 3 months of study entry, including unstable&#xD;
             or new onset angina, myocardial infarction or cerebrovascular accident&#xD;
&#xD;
          6. Women of child-bearing potential who are unable or unwilling to use an acceptable&#xD;
             method of contraception&#xD;
&#xD;
          7. Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C&#xD;
&#xD;
          8. Symptomatic congestive heart failure, defined as New York Heart Association Class II&#xD;
             or higher&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yosef Refaeli</last_name>
    <phone>+1-720-859-3547</phone>
    <email>refaeli@taigabiotech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vivienne Margolis</last_name>
    <phone>+972-52-4639634</phone>
    <email>vmargolis@taigabiotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Salomon Stemmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Malignant</keyword>
  <keyword>Refractory</keyword>
  <keyword>Resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

